🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Fostering Data Sharing

Search Papers Authors Institutions Grants FAIR About

TheSindex

Fostering Data Sharing

Empowering the data sharing that empowers science — an open, citation-grounded index for datasets.

Product

Search
API
Explore
Rankings

Resources

Methodology
Data Sources
Documentation
Press

Organization

About
Team
Wikidata

© 2026 theSindex. All rights reserved.

Home
Authors
Yunkai Yu

Yunkai Yu

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

3in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 3 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Top data-sharing exemplar

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Supplementary Figure from Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy

(2023)10.1158/1078-0432.22486571

Top 100%

0DataRank

Top 100%0 citations

Scot A. Niglio, Amir Mortazavi, Rosa Nadal, Primo N. Lara, Sumanta K. Pal +30 more

Papers

Driven by 13 papers — median percentile 0. Top paper: “Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy”.

Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-21-3726

N/A

1.1DataRank · unranked

24 citations

Scot A. Niglio, Amir Mortazavi, Rosa Nadal, Primo Lara, Sumanta K. Pal +30 more

Tofacitinib to prevent anti-drug antibody formation against LMB-100 immunotoxin in patients with advanced mesothelin-expressing cancers

Frontiers in Oncology(2024)10.3389/fonc.2024.1386190

N/A

0.421DataRank · unranked

9 citations

Cody J. Peer, Xianyu Zhang, Hyoyoung Choo‐Wosoba, Mehwish Ahmad, Min-Jung Lee +13 more

mRNA Vaccine-Induced Antibodies More Effective than Natural Immunity in Neutralizing SARS-CoV-2 and its High Affinity Variants

Research Square(2021)10.21203/rs.3.rs-659065/v1

N/A

0DataRank · unranked

0 citations

Dominic Esposito, Zhigang Kang, Jianming Lü, Alan T. Remaley, Leo Chen +4 more

mRNA vaccine-induced antibodies more effective than natural immunity in neutralizing SARS-CoV-2 and its high affinity variants

Scientific Reports(2022)10.1038/s41598-022-06629-2

N/A

0DataRank · unranked

44 citations

Dominic Esposito, Zhigang Kang, Jianming Lü, Alan T. Remaley, Valeria De Giorgi +4 more

Low serum mesothelin in pancreatic cancer patients results from retention of shed mesothelin in the tumor microenvironment

Translational Oncology(2022)10.1016/j.tranon.2022.101440

N/A

0DataRank · unranked

14 citations

Yunkai Yu, Cody J. Peer, Rebekah Landsman, Nebojša Skorupan, Liang Cao +2 more

Analysis of systemic immune changes in patients with advanced cancer treated with immunotoxin LMB-100 and tofacitinib.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.e15017

N/A

0DataRank · unranked

1 citations

Cody J. Peer, Yunkai Yu, Min-Jung Lee, Sunmin Lee, Shraddha Rastogi +10 more

Supplementary Figure from Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy

(2023)10.1158/1078-0432.22486571

Top 100%

0DataRank

Top 100%0 citations

Scot A. Niglio, Amir Mortazavi, Rosa Nadal, Primo N. Lara, Sumanta K. Pal +30 more

Supplementary Figure from Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy

Figshare(2023)10.1158/1078-0432.22486556.v1

Top 100%

0DataRank

Top 100%0 citations

Scot A. Niglio, Amir Mortazavi, Rosa Nadal, Primo N. Lara, Sumanta K. Pal +30 more

Data from Drozitumab, a Human Antibody to Death Receptor 5, Has Potent Antitumor Activity against Rhabdomyosarcoma with the Expression of Caspase-8 Predictive of Response

(2023)10.1158/1078-0432.c.6518703.v1

N/A

0DataRank · unranked

0 citations

Junjie Chen, Yunkai Yu, Bo Li, Shi‐Yong Sun, Baolin Zhang +2 more

Data from Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy

(2023)10.1158/1078-0432.c.6532346.v1

Top 100%

0DataRank

Top 100%0 citations

Scot A. Niglio, Amir Mortazavi, Rosa Nadal, Primo N. Lara, Sumanta K. Pal +30 more

Phase I study of mesothelin-targeted immunotoxin LMB-100 given as a long infusion with or without nab-paclitaxel.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.3553

N/A

0DataRank · unranked

2 citations

Mehwish Ahmad, Yunkai Yu, Akira Yuno, Min-Jung Lee, Cody J. Peer +8 more

AAV-mediated inner ear gene delivery triggers mild host immune responses in the mammalian inner ear

Molecular Therapy — Methods & Clinical Development(2025)10.1016/j.omtm.2025.101456

N/A

0DataRank · unranked

3 citations

Jianliang Zhu, Gwladys Gernoux, Yunkai Yu, Michelle J. Suh, Kevin Isgrig +8 more

Clinical characterization and cytokine profile of fatigue in hematologic malignancy patients with chronic graft-versus-host disease

Bone Marrow Transplantation(2021)10.1038/s41409-021-01419-2

N/A

0DataRank · unranked

7 citations

Leorey N. Saligan, Filip Pirsl, Noa G. Holtzman, Alen Ostojić, Seth M. Steinberg +9 more